Table 1.
Clinical information and diagnostic markers of the vaccinated patients
| Patients | % | |
|---|---|---|
| Total | 173 | 100% |
| Male | 117 | 68% |
| Female | 56 | 32% |
| Alive | 94 | 54% |
| Karnofsky performance status | ||
| 100 | 50 | 28% |
| 90 | 64 | 37% |
| 85 | 1 | 1% |
| 80 | 35 | 20% |
| 70 | 17 | 10% |
| 60 | 6 | 4% |
| Median age at diagnosis (years) | 53.1 | (range 9–87) |
| “7 gain combined with 10 loss” signature | 34 | 20% |
| EGFR gain of function (amplification and/or mutation) | 76 | 44% |
| TERT promoter status | ||
| Mutant | 143 | 83% |
| Wildtype | 30 | 17% |
| MGMT promoter status | ||
| Methylated | 75 | 43% |
| Unmethylated | 89 | 51% |
| Unknown | 9 | 5% |
| Therapy (during the course of the disease) | ||
| Radiation | 165 | 95% |
| Temozolomide | 167 | 97% |
| Glucocorticoids | 87 | 50% |
| Immune checkpoint inhibitor | 77 | 45% |
| Bevacizumab | 101 | 58% |
| Tumor status at personalized peptide treatment | ||
| Primary | 70 | 40% |
| Recurrent | 103 | 60% |
| Median time from diagnosis to personalized peptide vaccine treatment (months) | 10.3 | (range 3–54) |
| PD-L1 status (CP score >2) | ||
| Positive | 31 | 18% |
| Negative | 71 | 41% |
| Unknown | 70 | 40% |
| Unclear | 1 | 1% |
| Post-vaccination T-cell responses to in vitro stimulation with vaccinated peptides | ||
| Immunological responders | 77 | 45% |
| Immunological non-responders | 20 | 12% |
| Unknown (no immune monitoring) | 76 | 44% |
Source data are provided as a Source Data file.
EGFR epidermal growth factor receptor, MGMT methylguanine methyltransferase, PD-L1 programmed death ligand 1, TERT telomerase, CP combined positive score.